KR950010885A - 골 손실의 억제 방법 - Google Patents

골 손실의 억제 방법 Download PDF

Info

Publication number
KR950010885A
KR950010885A KR1019940026031A KR19940026031A KR950010885A KR 950010885 A KR950010885 A KR 950010885A KR 1019940026031 A KR1019940026031 A KR 1019940026031A KR 19940026031 A KR19940026031 A KR 19940026031A KR 950010885 A KR950010885 A KR 950010885A
Authority
KR
South Korea
Prior art keywords
alkyl
hydroxy
thien
methanone
phenyl
Prior art date
Application number
KR1019940026031A
Other languages
English (en)
Inventor
울만 브라이언트 헨리
알란 그리즈 티모시
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950010885A publication Critical patent/KR950010885A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 유효량의 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물을 골손실의 억제가 필요한 인간에게 투여함을 포함하는, 상기 골손실의 억제 방법을 제공한다.
상기식에서, R은 수소 : 하이드록시 : C₁내지 C6알콕시 : 일반식 -O-C(0)-Ra(여기에서 Ra는 수소 ; 아미노, 할로, 카보닐, C₁내지 C6알콕시카보닐, C₁내지 C7알카노일옥시, 카바모닐 및/또는 아릴로 임의로 치환된 C₁내지 C6알킬 : 또는 아릴로 임의로 치환된 C₁내지 C6알케닐 : 또는 C₃내지 C7사이클로알킬 : 또는 하이드록시, C₁내지 C6알킬, C1내지 C6알콕시 및/또는 할로로 임의로 치환된 아릴 : 또는 -0-아릴이고, 상기 아릴은 하이드록시, C1내지 C6알킬, C1내지 C6알콕시 및/또는 할로로 임의로 치환된다)의 그룹이거나 : 또는 일반식 -0-SO2-Rb는(여기서 Rb는 C1내지 C6알킬 또는 C1내지 C6알킬로 임의로 치환된 아릴일 수 있다)의 그룹이거나 : 또는 질소가 C7내지 C6알킬로 1회 또는 2회 치환될 수도 있는 카바모일옥시이나거나; 또는 일반식 -0-C(0)Rc-0-(C1내지 C6알킬)(여기에서 Rc는 결합 또는 C1내지 C6알칸디일이다)의 그룹이고; R1은 할로, C1내지 C6알킬, C1내지 C6알킬로 치환된 C1내지 C7알킬, 치환되거나 또는 비치환된 C₃내지 C7사이클로알킬, 또는 치환되거나 또는 비 치환된 C₃내지 C7사이클로알케닐이고; R2는 0또는 CH2이고; R3는 CH₂또는 (CH2)2이고; R4는, CH2또는 결합이고, R5는 아미노, C1내지 C6알킬로 1회 또는 2회 임의로 치환된 니트릴로; 또는 임의로 고리중에 N, 0또는 S중에서 선택된 또다른 헤테로 원자를 갖는 N-헤테로사이클릭고리이다.

Description

골 손실의 억제 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 골손실을 억제시키기 위한 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물;
    상기식에서, R은 수소 : 하이드록시 : C₁내지 C6알콕시 : 일반식 -0-C(0)-Ra(여기에서 Ra는 수소 ; 아미노, 할로, 카보닐, C₁내지 C6알콕시카보닐, C₁내지 C7알카노일옥시, 카바모닐 및/또는 아릴로 임의로 치환된 C₁내지 C6알킬 : 또는 아릴로 임의로 치환된 C₁내지 C6알케닐 : 또는 C₃내지 C7사이클로알킬 : 또는 하이드록시, C₁내지 C6알킬, C1내지 C6알콕시 및/또는 할로로 임의로 치환된 아릴 : 또는 -0-아릴이고, 상기 아릴은 하이드록시, C1내지 C6알킬, C1내지 C6알콕시 및/또는 할로로 임의로 치환된다)의 그룹이거나 : 또는 일반식 -0-SO2-Rb는(여기서 Rb는 C1내지 C6알킬 또는 C1내지 C6알킬로 임의로 치환된 아릴일 수 있다)의 그룹이거나 : 또는 질소가 C7내지 C6알킬로 1회 또는 2회 치환될 수도 있는 카바모일옥시이나거나; 또는 일반식 -0-C(0)Rc-0-(C1내지 C6알킬)(여기에서 Rc는 결합 또는 C1내지 C6알칸디일이다)의 그룹이고; R1은 할로, C1내지 C6알킬, C1내지 C6알킬로 치환된 C1내지 C7알킬, 치환되거나 또는 비치환된 C₃내지 C7사이클로알킬, 또는 치환되거나 또는 비 치환된 C₃내지 C7사이클로알케닐이고; R2는 0또는 CH2이고; R3는 CH₂또는 (CH2)2이고; R4는, CH2또는 결합이고, R5는 아미노, C1내지 C6알킬로 1회 또는 2회 임의로 치환된 니트릴로; 또는 임의로 고리중에 N, 0또는 S중에서 선택된 또다른 헤테로 원자를 갖는 N-헤테로사이클릭고리이다.
  2. 제1항에 있어서, R1이 C₁내지 C6알킬 또는 하이드록시로 치환될 수도 있는 탄소수 3내지 8의 사이클로알킬 그룹 또는 일반식
  3. 제1항에 있어서, (6-하이드록시-2-사이클로헥실벤조[b]티엔-3-일)[4-(2- (1-피롤리디닐)에톡시]페닐)메탄온, (6-하이드록시-2-사이클로헥실벤조[b]티엔-3-일)[4-[2-(1-피페리디닐)에톡시]페닐]메탄온,(6-하이드록시-2-사이클로헵틸벤조[b
    ]티엔-3-일)[4-[2-(1-피롤리디닐)에톡시]페닐]메탄온, (6-하이드록시-2-사이클로헵 틸벤조[b]티엔-3-일)[4-[2-(1-피페리디닐)에톡시]페닐]메탄온, (6-하이드록시-2-이소프로필벤조[b]티엔-3-일)[4-[2-(1-피롤리디닐)에톡시]페닐]메탄온, 또는 (6-하이드록시-2-이소프로핀벤조[b]티엔-3-일)[4-[2-(1-피페리디닐)에톡시]페닐]메탄온인 화합물.
  4. 제1항에 있어서, (6-하이드록시-2-사이클로헥실벤조[b]티엔-3-일)[4-[3- (1-피롤리디닐)프로필]페닐]메탄온, (6-하이드록시-2-사이클로헥실벤조[b]티엔-3-일)[4-[3-(1-피롤리디닐)프로필]페닐]메탄온, 또는 (6-하이드록시-2-사이클로헥실벤조[b]티엔-3-일)[4-[2-(1-피롤리디닐카보닐)에틸]페닐]메탄온인 화합물.
  5. 제1항에 있어서, (6-메톡시-2-사이클로헥실벤조[b]티엔-3-일)[4-[2-(1-피페리디닐]에톡시]페닐]메탄온 또는 (6-아세톡시-2-사이클로헥실벤조[b]티엔-3-일) [4-[2-(1-피페리디닐)에톡시]페닐)메탄온인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940026031A 1993-10-15 1994-10-12 골 손실의 억제 방법 KR950010885A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/137,878 US5441964A (en) 1993-10-15 1993-10-15 Methods for inhibiting bone loss using substituted benzothiophene
US8/137878 1993-10-15

Publications (1)

Publication Number Publication Date
KR950010885A true KR950010885A (ko) 1995-05-15

Family

ID=22479442

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026031A KR950010885A (ko) 1993-10-15 1994-10-12 골 손실의 억제 방법

Country Status (15)

Country Link
US (1) US5441964A (ko)
EP (1) EP0651998A1 (ko)
JP (1) JPH07188012A (ko)
KR (1) KR950010885A (ko)
CN (1) CN1105853A (ko)
AU (1) AU678849B2 (ko)
CA (1) CA2117854A1 (ko)
CZ (1) CZ250194A3 (ko)
HU (1) HUT72446A (ko)
IL (1) IL111224A0 (ko)
NO (1) NO943852L (ko)
NZ (1) NZ264649A (ko)
PH (1) PH31315A (ko)
RU (1) RU94037248A (ko)
ZA (1) ZA947933B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5550123A (en) * 1994-08-22 1996-08-27 Eli Lilly And Company Methods for inhibiting bone prosthesis degeneration
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
GB9610281D0 (en) * 1996-05-16 1996-07-24 Ralston Stuart H Diagnostic method and apparatus
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US5922753A (en) * 1996-10-23 1999-07-13 Zymogenetics, Inc. Methods for treating bone deficit conditions with benzothiazole
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6342514B1 (en) 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6251901B1 (en) 1996-10-23 2001-06-26 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5965573A (en) * 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5939444A (en) * 1996-10-23 1999-08-17 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6017940A (en) * 1996-10-23 2000-01-25 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US7201928B1 (en) 1999-09-21 2007-04-10 Rutgers, The State University Of New Jersey Extracts of orange peel for prevention and treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms

Also Published As

Publication number Publication date
RU94037248A (ru) 1996-11-10
AU678849B2 (en) 1997-06-12
ZA947933B (en) 1996-04-11
CZ250194A3 (en) 1995-05-17
JPH07188012A (ja) 1995-07-25
HUT72446A (en) 1996-04-29
NO943852D0 (no) 1994-10-12
NZ264649A (en) 1999-06-29
AU7577994A (en) 1995-05-04
CA2117854A1 (en) 1995-04-16
US5441964A (en) 1995-08-15
NO943852L (no) 1995-04-18
IL111224A0 (en) 1994-12-29
CN1105853A (zh) 1995-08-02
EP0651998A1 (en) 1995-05-10
HU9402963D0 (en) 1995-02-28
PH31315A (en) 1998-07-06

Similar Documents

Publication Publication Date Title
KR950010885A (ko) 골 손실의 억제 방법
KR950010886A (ko) 혈청 콜레스테롤의 강하 방법
KR950010894A (ko) 자궁 섬유증의 억제 방법
KR930700490A (ko) 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드
KR950010893A (ko) 자궁내막증 억제 방법
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
KR910006218A (ko) 2-아미도테트라린 치환유도체와 이 치환유도체를 포함하는 제약학적 조성물 및 이를 사용한 치료방법
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
ES2176204T3 (es) Antidepresivos que contienen un derivado de xantina.
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
HUP0100388A2 (hu) Készítmények és eljárások csontritkulás kezelésére és a koleszterinszint csökkentésére
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR900006342A (ko) 1,4-디아제핀 유도체 및 그의 약학적 이용
KR950010892A (ko) 자궁 섬유증 억제 방법
ATE161723T1 (de) Arzneimittel zur verwendung bei der behandlung von parkinsonismus
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
NO152047C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin
KR970704444A (ko) 트리아진 유도체 및 의약(triazine derivative and medicine)
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016735A (ko) 터너 증후군의 억제 방법
KR900018091A (ko) 진경제

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid